Catalyst Event
CLASSYS Inc (214150) · Earnings Release
From Akros SCHK HK-Korea Cosmetics Index (ASHKCOS)
5/13/2026, 12:00:00 AM
Announced preliminary Q1 2026 results on May 13, 2026. Revenue increased 13% YoY to KRW 87.2 billion, but operating profit decreased 4.1% YoY to KRW 37.2 billion, which was below market expectations.
Korean Translation
2026년 5월 13일 2026년 1분기 잠정 실적 발표. 매출은 전년 동기 대비 13% 증가한 872억 원을 기록했으나, 영업이익은 전년 동기 대비 4.1% 감소한 372억 원으로 시장 기대치를 하회함.
Related Recent Events
HLB Co Ltd (028300) · Other
FDA decision on New Drug Application for Lirafugratinib as a second-line treatment for bile duct cancer, which was granted priority review and carries an estimated >10% price impact, scheduled.
9/27/2026, 12:00:00 AM
HLB Co Ltd (028300) · Other
FDA decision on New Drug Application for Rivoceranib and Camrelizumab combination therapy as a first-line treatment for liver cancer, following a 'Class 2' resubmission in January 2026 and carrying an estimated >10% price impact, scheduled.
7/23/2026, 12:00:00 AM
Sino Biopharmaceutical Ltd (1177) · Other
The ex-dividend date for the proposed final dividend of HKD 0.05 per share is 2026-06-24, which is estimated to have a price impact of ≥1% scheduled.
6/24/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
SK Biopharmaceuticals Co Ltd (326030) · Other
SK Biopharmaceuticals is scheduled to be removed from the MSCI Korea Index effective at the close of May 29, 2026, following an announcement on May 12, 2026, which may lead to passive fund outflows, scheduled. Medium impact estimated due to expected passive fund outflows.
5/29/2026, 12:00:00 AM
CSPC Pharmaceutical Group Ltd (1093) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast revenue of 7.52B HKD. Estimated Medium importance as earnings results typically drive significant price movement scheduled.
5/27/2026, 12:00:00 AM